Clinical trial
Creatine Treatment in Psychiatric Disorders
NCT00140192 · Beersheva Mental Health Center, Other · Completed
Key facts
| NCT number | NCT00140192 |
|---|---|
| Title | Creatine Treatment in Psychiatric Disorders |
| Official title | Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial |
| Lead sponsor | Beersheva Mental Health Center, Other |
| Collaborators | National Alliance for Research on Schizophrenia and Depression |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | creatine |
| Enrollment | 12 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Jul 29, 2009 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: